Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elien Roose

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Blood Advances|September 8, 2021
Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpuraKadri Kangro, Elien Roose, Bérangère S Joly, et al.
Journal of Thrombosis and Haemostasis : JTH|January 29, 2020
Anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura do not hamper ELISA-based quantification of ADAMTS13 antigenCharlotte Dekimpe, Elien Roose, Claudia Tersteeg, et al.
Journal of Thrombosis and Haemostasis : JTH|September 21, 2022
ADAMTS13 inhibition to treat acquired von Willebrand syndrome during mechanical circulatory support device implantationShannen J Deconinck, Christoph Nix, Svenja Barth, et al.
Thrombosis and Haemostasis|September 21, 2018
Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic PurpuraElien Roose, Gestur Vidarsson, Kadri Kangro, et al.
Journal of Thrombosis and Haemostasis : JTH|November 10, 2020
Immunogenic hotspots in the spacer domain of ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpuraLeydi Carolina Velásquez Pereira, Elien Roose, Nuno A G Graça, et al.
Blood|September 12, 2018
Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpuraMatthieu Jestin, Ygal Benhamou, An-Sofie Schelpe, et al.
Blood|May 2, 2020
Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpuraElien Roose, An-Sofie Schelpe, Edwige Tellier, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Blood Advances|September 8, 2021
Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpuraKadri Kangro, Elien Roose, Bérangère S Joly, et al.
Journal of Thrombosis and Haemostasis : JTH|January 29, 2020
Anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura do not hamper ELISA-based quantification of ADAMTS13 antigenCharlotte Dekimpe, Elien Roose, Claudia Tersteeg, et al.
Journal of Thrombosis and Haemostasis : JTH|September 21, 2022
ADAMTS13 inhibition to treat acquired von Willebrand syndrome during mechanical circulatory support device implantationShannen J Deconinck, Christoph Nix, Svenja Barth, et al.
Thrombosis and Haemostasis|September 21, 2018
Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic PurpuraElien Roose, Gestur Vidarsson, Kadri Kangro, et al.
Journal of Thrombosis and Haemostasis : JTH|November 10, 2020
Immunogenic hotspots in the spacer domain of ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpuraLeydi Carolina Velásquez Pereira, Elien Roose, Nuno A G Graça, et al.
Blood|September 12, 2018
Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpuraMatthieu Jestin, Ygal Benhamou, An-Sofie Schelpe, et al.
Blood|May 2, 2020
Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpuraElien Roose, An-Sofie Schelpe, Edwige Tellier, et al.
Pageof 3